Carrageenan as an adjuvant to enhance peptide-based vaccine potency

Vaccine

Volumn 28, Issue 32, 2010, Pages 5212-5219

  Zhang, Yu Qian ^a   Tsai, Ya Chea ^a   Monie, Archana ^a   Hung, Chien Fu ^a   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Carrageenan; E7; Human papillomavirus (HPV); Peptide vaccination

Indexed keywords

CARRAGEENAN; HUMAN PAPILLOMAVIRUS TYPE 16 E7 PEPTIDE VACCINE; PEPTIDE VACCINE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; WART VIRUS VACCINE; CANCER VACCINE; DEXTRAN; IMMUNOLOGICAL ADJUVANT; LIPID A; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; PHOSPHORYL LIPID A; PROTEIN E7; SUBUNIT VACCINE; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CD8+ T LYMPHOCYTE; IMMUNOLOGY; KNOCKOUT MOUSE; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS INFECTIONS; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CARRAGEENAN; CD8-POSITIVE T-LYMPHOCYTES; DEXTRANS; FEMALE; LIPID A; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TOLL-LIKE RECEPTOR 4; VACCINES, SUBUNIT;

EID: 77954955758     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.068     Document Type: Article

References (21)

1. Hung C.F., Ma B., Monie A., Tsen S.W., Wu T.C. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther 2008, 8(4):421-439.
2. Hung C.F., Wu T.C., Monie A., Roden R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev 2008, 222:43-69.
3. Rudolf M.P., Man S., Melief C.J., Sette A., Kast W.M. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res 2001, 7(3 Suppl.):788s-795s.
4. van der Burg S.H., Ressing M.E., Kwappenberg K.M., de Jong A., Straathof K., de Jong J., et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 2001, 91(5):612-618.
5. Brinkman J.A., Fausch S.C., Weber J.S., Kast W.M. Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 2004, 4(2):181-198.
6. Kanodia S., Kast W.M. Peptide-based vaccines for cancer: realizing their potential. Expert Rev Vaccines 2008, 7(10):1533-1545.
7. Crook T., Morgenstern J.P., Crawford L., Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J 1989, 8(2):513-519.
8. Zwaveling S., Ferreira Mota S.C., Nouta J., Johnson M., Lipford G.B., Offringa R., et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002, 169(1):350-358.
9. Guermonprez P., Valladeau J., Zitvogel L., Thery C., Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002, 20:621-667.
10. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5(10):987-995.
11. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406(6797):782-787.
12. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4(7):499-511.
13. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2(8):675-680.
14. Bhattacharyya S., Gill R., Chen M.L., Zhang F., Linhardt R.J., Dudeja P.K., et al. Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells. J Biol Chem 2008, 283(16):10550-10558.
15. Chapter III: Properties, Manufacture and Application of Seaweed polysaccharides - agar, carrageenan and algin. In: FAO Corporate Document Repository Training manual on Gracilaria culture and seaweed processing in China Regional Seafarming Development and Demonstration Project report No.6, (1990) p. 107.
16. Buck C.B., Thompson C.D., Roberts J.N., Muller M., Lowy D.R., Schiller J.T. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2006, 2(7):e69.
17. Lin K.-Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996, 56:21-26.
18. Chen C.-H., Wang T.-L., Hung C.-F., Yang Y., Young R.A., Pardoll D.M., et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000, 60:1035-1042.
19. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003, 2(2):219-229.
20. Bend J., Bolger M., Knaap A.G., Kuznesof P.M., Larsen J.C., Mattia A., et al. Evaluation of certain food additives and contaminants. World Health Organ Tech Rep Ser 2007, (947):1-225. back cover.
21. Tobacman J.K. Review of harmful gastrointestinal effects of carrageenan in animal experiments. Environ Health Perspect 2001, 109(10):983-994.